Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million, three-year Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Akonni received the Phase I contract in August 2016.
{iframe}https://biobuzz.inloop.com/en/article/69226/mriglobal-to-test-system-for-akonni-biosystems-device?id=69226{/iframe}